Hailed as the biggest biotech licensing deal ever, Genmab A/S' potential DKK12 billion (US$2.1 billion) pact with London-based GlaxoSmithKline plc gives the London-based pharma giant worldwide rights to the late-stage HuMax-CD20, and a stake of just more than 10 percent in Genmab. (BioWorld Today)
Exelixis Inc.'s potential $120 million deal for cancer drugs with Bristol-Myers Squibb Co. broadens the two firms' longstanding relationship in oncology, providing $60 million up front while letting Exelixis keep sole ownership of a substantial pipeline. (BioWorld Today)
Awaiting a decision from overseas regulators on the chemotherapy booster Genasense for advanced melanoma, Genta Inc. is deciding its next steps in the U.S., after the FDA declared the product non-approvable for chronic lymphocytic leukemia. (BioWorld Today)
